156 related articles for article (PubMed ID: 17020453)
1. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Astsaturov I; Cohen RB; Harari P
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1179-93. PubMed ID: 17020453
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
4. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer.
Wang SJ; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2006 Jul; 132(7):771-8. PubMed ID: 16847188
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.
Thomas SM; Coppelli FM; Wells A; Gooding WE; Song J; Kassis J; Drenning SD; Grandis JR
Cancer Res; 2003 Sep; 63(17):5629-35. PubMed ID: 14500405
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor in head and neck cancer.
Ford AC; Grandis JR
Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?
Raben D; Bianco C; Milas L; Ang KK
Semin Radiat Oncol; 2004 Apr; 14(2):139-52. PubMed ID: 15095260
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted therapy of head and neck cancer: review and clinical development challenges.
Le Tourneau C; Faivre S; Siu LL
Eur J Cancer; 2007 Nov; 43(17):2457-66. PubMed ID: 17904355
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
16. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
17. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
19. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.
Patel V; Rosenfeldt HM; Lyons R; Servitja JM; Bustelo XR; Siroff M; Gutkind JS
Carcinogenesis; 2007 Jun; 28(6):1145-52. PubMed ID: 17234718
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.
Bernier J
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1193-208, ix. PubMed ID: 19010268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]